← Leaderboards
Sonia Hernandez-Diaz
Harvard School Of Public Health
$14,346,574
Attributed
$19,763,879
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $20.5M · FY2009–25$25M$18.8M$12.5M$6.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$105,836,675 · 9
AHRQ$2,231,532 · 1
By mechanism
P01$88,304,328 · 1
R01$17,459,962 · 7
T32$1,826,207 · 1
R21$477,710 · 1
Top collaborators
- Ellen Gould Chadwick9 shared
- Jennifer Jao9 shared
- Allen A Mitchell9 shared
- Paige L Williams9 shared
- Miguel Hernan5 shared
- John Hsu5 shared
- Henning Tiemeier5 shared
Most similar at Harvard School Of Public Health
Same institution · by research overlap
- Michele R. Decker$5,948,529
Others in their field
Top investigators on “Exposure To”
- Chanza Baytop · Westat, Inc.$271,217,917
- Dennis R. Burton · Scripps Research Institute$265,781,207
- Myron S Cohen · Family Health International$253,611,624
- Wafaa M. El-Sadr · Columbia University Health Sciences$253,611,624
- George R Seage · Abt Associates, Inc.$221,990,872
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$151,998,810
Research focus
Exposure ToInfantPregnant WomenPharmaceutical PreparationsSafetyPregnancyCohortReproductiveEpidemiologyAdultMalformationInfectionGuidelinesCharacteristicsChildBirthToxic EffectDiabetes MellitusMedicalBaseConfidence IntervalsDatabasesFetalPopulation Based
Grant awards (46)
Impact of obesity treatments on subsequent pregnancy outcomes$659,135
R01 · FY2025 · HD · contact PI
The Training Program in Reproductive, Perinatal, and Pediatric Life Course Epidemiology$384,512
T32 · FY2025 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,150,732
P01 · FY2024 · HD
The Training Program in Reproductive, Perinatal, and Pediatric Life Course Epidemiology$376,789
T32 · FY2024 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$217,850
P01 · FY2024 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,150,816
P01 · FY2023 · HD
Comparative Safety of Non-Insulin Agents in Pregnant Women with Pregestational Diabetes$562,217
R01 · FY2023 · HD · contact PI
The Training Program in Reproductive, Perinatal, and Pediatric Life Course Epidemiology$366,003
T32 · FY2023 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,600,741
P01 · FY2022 · HD
Comparative Safety of Non-Insulin Agents in Pregnant Women with Pregestational Diabetes$562,217
R01 · FY2022 · HD · contact PI
Long-term Impact of Fertility Treatment Study$540,673
R01 · FY2022 · HD
The Training Program in Reproductive, Perinatal, and Pediatric Life Course Epidemiology$359,931
T32 · FY2022 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,457,932
P01 · FY2021 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$803,491
P01 · FY2021 · HD
Comparative Safety of Non-Insulin Agents in Pregnant Women with Pregestational Diabetes$564,210
R01 · FY2021 · HD · contact PI
Long-term Impact of Fertility Treatment Study$541,816
R01 · FY2021 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$450,000
P01 · FY2021 · HD
The Training Program in Reproductive, Perinatal, and Pediatric Life Course Epidemiology$338,972
T32 · FY2021 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$322,285
P01 · FY2021 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,150,481
P01 · FY2020 · HD
Comparative Safety of Non-Insulin Agents in Pregnant Women with Pregestational Diabetes$577,080
R01 · FY2020 · HD · contact PI
Long-term Impact of Fertility Treatment Study$552,873
R01 · FY2020 · HD
Comparative Safety of Non-Insulin Agents in Pregnant Women with Pregestational Diabetes$652,693
R01 · FY2019 · HD · contact PI
Long-term Impact of Fertility Treatment Study$563,241
R01 · FY2018 · HD
Pregnancy Registries Nested in International Pooled Health Care Databases$211,537
R21 · FY2018 · HD · contact PI
Long-term Impact of Fertility Treatment Study$665,167
R01 · FY2017 · HD
Pregnancy Registries Nested in International Pooled Health Care Databases$266,173
R21 · FY2017 · HD · contact PI
Comparative Safety of commonly prescribed Psychotropic Drugs in pregnant Women$421,895
R01 · FY2016 · MH · contact PI
Comparative Safety of commonly prescribed Psychotropic Drugs in pregnant Women$458,865
R01 · FY2015 · MH · contact PI
Comparative Safety of commonly prescribed Psychotropic Drugs in pregnant Women$531,296
R01 · FY2014 · MH · contact PI
Comparative Effectiveness and Safety of Depression Treatments during Pregnancy$458,335
R01 · FY2013 · HS · contact PI
Phthalates in Drugs and Male Genital Malformation$648,116
R01 · FY2012 · HD · contact PI
Comparative Effectiveness and Safety of Depression Treatments during Pregnancy$459,296
R01 · FY2012 · HS · contact PI
Phthalates in Drugs and Male Genital Malformation$647,384
R01 · FY2011 · HD · contact PI
Comparative Effectiveness and Safety of Depression Treatments during Pregnancy$410,000
R01 · FY2011 · HS · contact PI
Teratogenicity of drugs commonly used in pregnancy$405,376
R01 · FY2011 · HD
Assessment of Infant Outcomes After in Utero Exposure to Antiretroviral Therapy$1,126,500
R01 · FY2010 · HD · contact PI
Teratogenicity of drugs commonly used in pregnancy$928,060
R01 · FY2010 · HD
Phthalates in Drugs and Male Genital Malformation$657,654
R01 · FY2010 · HD · contact PI
Teratogenicity of drugs commonly used in pregnancy$571,940
R01 · FY2010 · HD
Comparative Effectiveness and Safety of Depression Treatments during Pregnancy$450,993
R01 · FY2010 · HS · contact PI
Teratogenicity of drugs commonly used in pregnancy$411,227
R01 · FY2010 · HD
Assessment of Infant Outcomes After in Utero Exposure to Antiretroviral Therapy$1,058,509
R01 · FY2009 · HD · contact PI
Phthalates in Drugs and Male Genital Malformation$521,040
R01 · FY2009 · HD · contact PI
Comparative Effectiveness and Safety of Depression Treatments during Pregnancy$452,908
R01 · FY2009 · HS · contact PI
Teratogenicity of drugs commonly used in pregnancy$399,246
R01 · FY2009 · HD